Secarna Pharmaceuticals GmbH: LNAplus™ based antisense therapies have the potential to demonstrate superior safety and efficacy benefits over other modalities in development and on the market.
Secarna's uniquely efficient LNAplus™ discovery process is fueled by their proprietary and streamlined Oligofyer™ bioinformatics systems large in-house cell library and
own in vitro screening assays.
For subsequent pre-clinical development, Secarna's molecule design and selection work is complemented by partnerships with internationally renowned centers of excellence across academia and industry.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Pre-Clinical Stage
Disease Space
Immunotherapy
Listing
Private
Market Cap
Private
Website:
Profiles:
Address:
Am Klopferspitz 19
Planegg, Bayern 82152
Germany

Company Participants at Solebury Trout Virtual Management Access Event - 1x1 conference calls

  • Jonas Renz, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.